Login to Your Account



Celltech Details Phase III Trial Plans For CDP870 In Crohn's

By Aaron Lorenzo


Wednesday, January 7, 2004
A Phase III program in Crohn's disease is under way to evaluate a compound being developed by Celltech Group plc. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription